PI3K inhibitors are finally coming of age. (2021)

First Author: Vanhaesebroeck B
Attributed to:  Validation of the Vps34 PI 3-kinase as a new potential drug target in insulin sensitization funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.71501

Publication URI: https://www.repository.cam.ac.uk/handle/1810/324041

Type: Journal Article/Review